Journal of the American College of Cardiology Publishes European Study Results for Abiomed Impella 2.5

DANVERS, Mass.--(BUSINESS WIRE)--Results from the Europella registry, evaluating the safety and feasibility of the Abiomed, Inc. (NASDAQ: ABMD) Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures have been published in the December 15 issue of the Journal of the American College of Cardiology (JACC). The paper, “Supported High-Risk Percutaneous Coronary Intervention Using the Impella 2.5 device: The Europella Registry” concludes, “this large multicenter registry supports the safety, feasibility and potential usefulness of hemodynamic support with Impella 2.5 in high-risk PCI.”